Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)
China · Delayed Price · Currency is CNY 10.14
+0.16 (1.60%)
At close: May 8, 2026
SHE:301301 Revenue
Yili Chuanning Biotechnology had revenue of 1.09B CNY in the quarter ending March 31, 2026, a decrease of -15.61%. This brings the company's revenue in the last twelve months to 4.41B, down -20.21% year-over-year. In the year 2025, Yili Chuanning Biotechnology had annual revenue of 4.62B, down -19.83%.
Revenue (ttm)
4.41B
Revenue Growth
-20.21%
P/S Ratio
5.12
Revenue / Employee
1.41M
Employees
3,126
Market Cap
22.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.62B | -1.14B | -19.83% |
| Dec 31, 2024 | 5.76B | 934.97M | 19.38% |
| Dec 31, 2023 | 4.82B | 1.00B | 26.24% |
| Jan 1, 2023 | 3.82B | 588.64M | 18.21% |
| Jan 1, 2022 | 3.23B | -417.40M | -11.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Tiantan Biological Products | 5.99B |
| Hualan Biological Engineering | 4.49B |
| Xiamen Amoytop Biotech | 3.82B |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Suzhou Zelgen Biopharmaceuticals | 1.55B |
| Sinocelltech Group | 1.36B |
| Jinyu Bio-technology | 1.33B |